Dyania Health raises $5.3M to help speed up clinical trials

clinical trials

Dyania Health was founded in 2019 to address a significant and unsolved problem for clinical trials

That is, the process of manual chart review to pre-screening patients for clinical research is cumbersome and time-consuming. The process to match patients on very specific and time-sensitive clinical trial criteria typically takes 18 to 24 months for most trials.

Within oncology alone, there are approximately two million new patients per year in the U.S. These patients’ histories are also dynamically changing over time as their diseases progress, often quickly. Hence, an army of clinical research associates constantly reading ever-changing sets of EMR files is an impossible feat, and as a result, patients are often never found. 

Finding a “needle in a timestack,” within a patient’s window of opportunity, could mean qualification, access, and potential enrollment in a clinical study for a drug that could be an additional, life-saving care option for a patient who has exhausted other avenues.

Dyania Health’s approach accelerates clinical trials

The HIPAA compliant technology Dyania Health is building takes a prescriptive, rule-based approach, utilizing in-house medical and scientific expertise to drive optimal clinical research, bring drugs to market faster, improve patient outcomes, and save patient lives.

John Chelico, chief medical information officer of Common Spirit and former chief information officer of Northwell Health said: “Dyania Health’s approach to working with large health systems quickly creates a safe IT environment that unlocks and de-identifies the unstructured patient data from electronic health record databases. This process will be instrumental in accelerating the throughput of clinical trials accrual in a safe and compliant way.”

To fuel scale of algorithms and engineering, product development, and pharmaceutical client support, Dyania Health has announced the close of a $5.3 million seed round, led by Innospark Ventures

Also participating in the round were Outsiders Fund, Wild Basin, Big Pi Ventures, and Tau Ventures with recent investment from Genesis Ventures and TLife Investments.

Newsletter Signup - Under Article / In Page

"*" indicates required fields

Subscribe to our newsletter to get the latest biotech news!

This field is for validation purposes and should be left unchanged.

Suggested Articles

Show More